Biomarkers in Pulmonary Hypertension Associated to Interstitial Lung Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00820729|
Recruitment Status : Completed
First Posted : January 12, 2009
Last Update Posted : September 18, 2012
The presence of an abnormally increased pulmonary blood pressure worsens the prognosis of patients with interstitial pulmonary disease.
The aim of this study is to estimate the frequency of an increased blood pressure in the lungs among patient with interstitial pulmonary disease, and to evaluate the use of different biomarkers in diagnosis of the condition.
|Condition or disease|
|Interstitial Lung Disease Pulmonary Hypertension Biomarkers|
The presence of increased pulmonary blood pressure is established by echocardiography and confirmed by right heart catheterization.
The ability of NT-proBNP, vWf, troponin-t, D-dimer and exhaled NO to predict the presence of increased pressure in the pulmonary circulation is evaluated.
|Study Type :||Observational|
|Actual Enrollment :||212 participants|
|Official Title:||The Prevalence of Pulmonary Hypertension and the Significance of Different Biomarkers in Chronic Interstitial Lung Disease|
|Study Start Date :||March 2009|
|Actual Primary Completion Date :||March 2011|
|Actual Study Completion Date :||March 2011|
Patients with interstitial pulmonary disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00820729
|Department of Cardiology, Skejby sygehus|
|Århus N, Denmark, DK-8200|
|Department of Pulmonary Diseases, Århus Sygehus|
|Århus, Denmark, Dk-8000|